The University of Texas MD Anderson Cancer Center - Biology Summer Internship by Fortoul, Marla
BIOLOGY SUMMER INTERNSHIP
MARLA FORTOUL 
SUMMER UNDERGRADUATE PROGRAM AT 
MD ANDERSON CANCER CENTER
 10 weeks program 
 MD Anderson Cancer Center in Houston, Texas. 
 Students will be matched with a faculty mentor in 
any number of areas of biomedical 
research where a project will be assigned.
 Participants work alongside the mentor in a lab or 
clinic on projects designed by faculty to reflect 
current research. 
 Workshops and lectures provide opportunities to 
connect with faculty, residents, postdoctoral and 
clinical fellows, and other participants. 
 Through the program, students assess goals 
related to careers in oncology research and 
patient care. 
 Symposium in which participants present talks and 
posters on their research projects to peers and 
faculty. 
WHY SHOULD YOU GO TO MD ANDERSON ?
 Discover Possible Career Paths
 Networking opportunities
 Learning multiple techniques
 Shadowing Physicians 
 Oncology 
 PhD
 MD/PhD 
 Workshops
 Simulation Center 
 Speech Elevator 
 Cancer 
 Meet Students from all over the country 
 Learn about advancements in science
 Experience for Resume
 Research and clinical 
 Being at MD Anderson 
 Best Hospital in Cancer Care
 Groundbreaking research 
 Innovative Clinical Care
 Clinical Trials 
 Patients travel all over the world to be treated at 
MD Anderson
PROJECT
DETERMINE THE EFFECT OF IBRUTINIB ON 
HUMAN T CELLS.
 Department of Stem Cell Transplantation
 PI: Qing Ma, PhD
 Dan Li, Sr. Researcher
IBRUTINIB
 Therapy for B-cell malignancies
 Chronic Lymphocytic Leukemia: 
 It develops slowly, creating defective white 
blood cells that can’t produce antibodies 
against infection. 
 The average age of patients at diagnosis is 72. 
 Most Common type of Leukemia 
 Effects of Ibrutinib: 
 Inhibits Bruton’sTyrosine Kinase (BTK)
 Blocks downstream B cell receptor 
activation.
 Investigating the drug’s effect on Inducible T 
cell Kinase (ITK)
 Determine the effect on T cell receptor 
and T cell proliferation. 
PROJECTS
 Human T-Cell Activation  Human CD4 T Cell 
Proliferation 
 Human T Cell Counts 
Inhibited in the Presence 
of Ibrutinib
 Human CD4 T cell 
Proliferation in the 
Presence of Ibrutinib
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Introduction
Ibrutinib, is an orally active agent, which
works by covalent irreversible binding of
Cys-481 in the kinase domain of Bruton’s
Tyrosine Kinase (BTK).1-2 BTK is a non-
receptor tyrosine kinase of the Tec-kinase
family and is of central importance in B-cell
receptor (BCR) signaling. 3
In addition to BTK inhibition, it has been
hypothesized Ibrutinib as a target of
Interleukin-2 Inducible Kinase (ITK) due to
significant homology with BTK. ITK is a T
cell dominant member of the TEC-kinase
family that drives proximal T-cell receptor
(TCR) signaling.4 ITK is active in T-cell
malignancies and has been linked to tumor
immune invasion and survival through its
critical role in T helper type 2 (Th2) cell
differentiation, making it an attractive
therapeutic target.5
Conclusions
Human T cells can be activated in
vitro by using CD3+CD28 mAb. CFSE
assay measured human CD4 T cell
proliferation showing increased division
when stimulated with CD3+CD28 mAb.
Furthermore, subsets of human T-cells,
CD4 and CD8, can be identified using
surface markers. Also, subsets of CD4 and
CD8 are positive for CD45RA and CCR7
staining markers. These markers allow the
identification of naïve, central memory,
effector memory, and TEMRA CD4 and
CD8 human T cells.
It was identified a reduced number of
activated human T cells in vitro as Ibrutinib
concentration increased until it reached 5
µM which lead to toxicity for the cells
resulting in reduced number of cells and
increased cell death. CFSE assay
measured human CD4 T cells proliferation
in the presence of Ibrutinib, it showed an
inhibition of CD4 T cells. The proliferation
index of CD4 T cells decreased as the
concentration of Ibrutinib increased, it
decreased exponentially after 1 µM.
In conclusion, Ibrutinib inhibits human
T cells proliferation, in particular CD4 T
cells. The inhibition is dose dependent and
starts becoming toxic for the cells at 5 µM.
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Materials and Methods
• PBMCs Isolation
Peripheral blood mononuclear cells
(PBMCs) were isolated via density gradient
centrifugation over Ficoll-Paque from buffy coat
preparations derived from whole blood of healthy
volunteer donors (Gulf Coast Regional Blood
Center, Houston, TX).
• Tissue Culture
PBMCs were cultured in a 96-well V-
bottom plate in culture media (RPMI 1640, 10%
FBS, and 1% P/S) at 0.2 x 106 cells/well. Cultured
cells were stimulated using 1 µg/mL anti-CD3 and 1
µg/mL anti-CD28 mAb for 6 days.
• CFSE Proliferation
A CellTrace CFSE Stock thawed and
diluted in phosphate-buffered saline (PBS). T cells
were resuspended in 1 mL of PBS with CFSE and
incubated for 2 minutes at room temperature. Cells
were washed and resuspended in culture media to
stabilize CFSE staining to track cell division.
• Ibrutinib
An Ibrutinib stock concentration of 100
mM was diluted into different concentrations (0, 0.5,
1, 5, and 10 µM) using DMSO. 1 µL of different
concentrations of Ibrutinib were added to PBMCs
cell culture.
• Flow Cytometry
Cultured T cells were stained with
monoclonal antibodies (CD4-PE, CD8-APC, CFSE-
FITC, CCR7-Pe-Cy, and CD45RA-PB) Samples
were acquired on Canto II Analyzer using
Fluorescence-activated cell sorting and analyzed
with FlowJo.
Human T-Cell Activation
Figure 1. Human T Cell Activation.
Human PBMCs were stimulated with
CD3+CD28 Ab for 6 days. They were
stained for expression of CD4, CD8,
CCR7, and CD45RA. Results depict (a)
SSC and FSC plot with gated live
lymphocytes, (b) contour plot of
expression of gated CD4 and CD8 from
live lymphocytes population, (c) CD4 and
CD8 gated cells were separated into four
subsets (CM= central memory, N=Naive,
TEMRA= terminal differentiated, and EM=
effector memory) based on CD45RA and
CCR7 labeling. (d) Column graphs
comparing Subsets of CD4 and CD8 T
cells between stimulated and
unstimulated T cells.
B
Human CD4 T Cell Proliferation 
Figure 2. Human T Cell Proliferation
using CFSE assay. CFSE assay CD4 T
cells stimulated with CD3+CD28 mAB
for 6 days. (a) Unstimulated CD4 cells
with 1 generation. (b) Stimulated CD4
cells with 6 generations.
Results Human T Cell Counts Inhibited 
in the Presence of Ibrutinib
Human CD4 T cell Proliferation in the 
Presence of Ibrutinib
Objectives
Determine the effect of Ibrutinib on human T
cells.
Figure 3. Human T Cell Inhibited in the
Presence of Ibrutinib. CFSE labeled T
cells stimulated with CD3+CD28 Ab for 6
days with different concentrations of
Ibrutinib (0, 0.5, 1, 5, and 10 µM). (a)
Results depict SSC and FSC plot with
gated live lymphocytes for unstimulated and
stimulated cells with various concentrations
of Ibrutinib. (b) Column graph showing
number of lymphocytes in each group.
Contact Information
Marla Fortoul
Nova Southeastern University, SURP at MD Anderson
marlacarolinafortoul1997@gmail.com
Figure 4. Human CD4 T cell
Proliferation in the Presence of
Ibrutinib. CFSE labeled T-cells stimulated
with CD3+CD28 for 6 days with different
concentrations of Ibrutinib (0, 0.5, 1, 5, and
10 µM). Results depict a histogram
showing the proliferation of CD4 cells. (B)
Column Graph depicting the division index
for unstimulated and stimulated CD4 cells
with different concentrations of Ibrutinib.
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APPLICATION 
REQUIREMENTS
 Nova Southeastern registered Halmos College junior or senior 
for fall 2019 with:
 Science GPA 3.0+ and cumulative GPA 3.0+.
 Successfully completed: Anatomy & Physiology, Medical 
Terminology, and Statistics.
 Preference to students with upper-level courses.
 Complete application submitted by October 26, 2018 including:
 Transcript or the CAPP report equivalent
 Personal Statement
 3 Letters of Recommendation
 Application can be found online 
at https://cnso.nova.edu/biology/index.html under 
Summer Internships.
 If qualified, committee interview. 
Contact Information:
• Dr. Mark Jaffe, mjaffe@nova.edu
• Dr. Deanne Roopnarine, 
roopnari@nova.edu
• Dr. Aarti Raja, araja@nova.edu.
• Marla Fortoul, 
mf1612@mynsu.nova.edu
